Stress as risk factor for Alzheimer's disease

Alessandra Caruso, Ferdinando Nicoletti, Dalila Mango, Amira Saidi, Rosamaria Orlando, Sergio Scaccianoce

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

Prolonged stress predisposes susceptible individuals to a number of physiological disorders including cardiovascular disease, obesity and gastrointestinal disorders, as well as psychiatric and neurodegenerative disorders. Preclinical studies have suggested that manipulation of the glucocorticoid milieu can trigger cellular, molecular and behavioral derangement resembling the hallmarks of Alzheimer's Disease (AD). For example, stress or glucocorticoid administration can increase amyloid ß precursor protein and tau phosphorylation which are involved in synaptic dysfunction and neuronal death associated with AD. Although since AD was first described in 1906 at a conference in Tubingen, Germany by Alois Alzheimer our knowledge of neuropathological and neurochemical alterations of AD has been impressively increased, at present, pharmacotherapy is symptomatic at best and has no influence on the progression of the disorder. It is generally believed that most of the drugs developed as disease modifiers have failed in clinical trials because treatment started too late, i.e., after the clinical onset of AD. Because AD pathology begins several years prior to the clinical diagnosis, it is imperative to identify subjects at high risk to develop the disorder. Consequently, the search for putative risk factors has gained importance. ApoE4, diabetes/metabolic syndrome, cardiovascular disorders, and a low cognitive reserve are established risk factors for AD. The focus of this review is on stress and glucocorticoids as potential factors increasing the risk to develop AD.

Original languageEnglish
Pages (from-to)130-134
Number of pages5
JournalPharmacological Research
Volume132
DOIs
Publication statusPublished - Jun 1 2018

Fingerprint

Alzheimer Disease
Glucocorticoids
Cognitive Reserve
Metabolic Syndrome X
Apolipoprotein E4
Amyloid beta-Protein Precursor
Neurodegenerative Diseases
Germany
Psychiatry
Cardiovascular Diseases
Obesity
Phosphorylation
Clinical Trials
Pathology
Drug Therapy
Pharmaceutical Preparations

Keywords

  • Alzheimer's disease
  • Animal model
  • Glucocorticoids
  • Risk factor
  • Stress

ASJC Scopus subject areas

  • Pharmacology

Cite this

Caruso, A., Nicoletti, F., Mango, D., Saidi, A., Orlando, R., & Scaccianoce, S. (2018). Stress as risk factor for Alzheimer's disease. Pharmacological Research, 132, 130-134. https://doi.org/10.1016/j.phrs.2018.04.017

Stress as risk factor for Alzheimer's disease. / Caruso, Alessandra; Nicoletti, Ferdinando; Mango, Dalila; Saidi, Amira; Orlando, Rosamaria; Scaccianoce, Sergio.

In: Pharmacological Research, Vol. 132, 01.06.2018, p. 130-134.

Research output: Contribution to journalReview article

Caruso, A, Nicoletti, F, Mango, D, Saidi, A, Orlando, R & Scaccianoce, S 2018, 'Stress as risk factor for Alzheimer's disease', Pharmacological Research, vol. 132, pp. 130-134. https://doi.org/10.1016/j.phrs.2018.04.017
Caruso, Alessandra ; Nicoletti, Ferdinando ; Mango, Dalila ; Saidi, Amira ; Orlando, Rosamaria ; Scaccianoce, Sergio. / Stress as risk factor for Alzheimer's disease. In: Pharmacological Research. 2018 ; Vol. 132. pp. 130-134.
@article{686b03f001234b6ab9ec023eea5569c2,
title = "Stress as risk factor for Alzheimer's disease",
abstract = "Prolonged stress predisposes susceptible individuals to a number of physiological disorders including cardiovascular disease, obesity and gastrointestinal disorders, as well as psychiatric and neurodegenerative disorders. Preclinical studies have suggested that manipulation of the glucocorticoid milieu can trigger cellular, molecular and behavioral derangement resembling the hallmarks of Alzheimer's Disease (AD). For example, stress or glucocorticoid administration can increase amyloid {\ss} precursor protein and tau phosphorylation which are involved in synaptic dysfunction and neuronal death associated with AD. Although since AD was first described in 1906 at a conference in Tubingen, Germany by Alois Alzheimer our knowledge of neuropathological and neurochemical alterations of AD has been impressively increased, at present, pharmacotherapy is symptomatic at best and has no influence on the progression of the disorder. It is generally believed that most of the drugs developed as disease modifiers have failed in clinical trials because treatment started too late, i.e., after the clinical onset of AD. Because AD pathology begins several years prior to the clinical diagnosis, it is imperative to identify subjects at high risk to develop the disorder. Consequently, the search for putative risk factors has gained importance. ApoE4, diabetes/metabolic syndrome, cardiovascular disorders, and a low cognitive reserve are established risk factors for AD. The focus of this review is on stress and glucocorticoids as potential factors increasing the risk to develop AD.",
keywords = "Alzheimer's disease, Animal model, Glucocorticoids, Risk factor, Stress",
author = "Alessandra Caruso and Ferdinando Nicoletti and Dalila Mango and Amira Saidi and Rosamaria Orlando and Sergio Scaccianoce",
year = "2018",
month = "6",
day = "1",
doi = "10.1016/j.phrs.2018.04.017",
language = "English",
volume = "132",
pages = "130--134",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press",

}

TY - JOUR

T1 - Stress as risk factor for Alzheimer's disease

AU - Caruso, Alessandra

AU - Nicoletti, Ferdinando

AU - Mango, Dalila

AU - Saidi, Amira

AU - Orlando, Rosamaria

AU - Scaccianoce, Sergio

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Prolonged stress predisposes susceptible individuals to a number of physiological disorders including cardiovascular disease, obesity and gastrointestinal disorders, as well as psychiatric and neurodegenerative disorders. Preclinical studies have suggested that manipulation of the glucocorticoid milieu can trigger cellular, molecular and behavioral derangement resembling the hallmarks of Alzheimer's Disease (AD). For example, stress or glucocorticoid administration can increase amyloid ß precursor protein and tau phosphorylation which are involved in synaptic dysfunction and neuronal death associated with AD. Although since AD was first described in 1906 at a conference in Tubingen, Germany by Alois Alzheimer our knowledge of neuropathological and neurochemical alterations of AD has been impressively increased, at present, pharmacotherapy is symptomatic at best and has no influence on the progression of the disorder. It is generally believed that most of the drugs developed as disease modifiers have failed in clinical trials because treatment started too late, i.e., after the clinical onset of AD. Because AD pathology begins several years prior to the clinical diagnosis, it is imperative to identify subjects at high risk to develop the disorder. Consequently, the search for putative risk factors has gained importance. ApoE4, diabetes/metabolic syndrome, cardiovascular disorders, and a low cognitive reserve are established risk factors for AD. The focus of this review is on stress and glucocorticoids as potential factors increasing the risk to develop AD.

AB - Prolonged stress predisposes susceptible individuals to a number of physiological disorders including cardiovascular disease, obesity and gastrointestinal disorders, as well as psychiatric and neurodegenerative disorders. Preclinical studies have suggested that manipulation of the glucocorticoid milieu can trigger cellular, molecular and behavioral derangement resembling the hallmarks of Alzheimer's Disease (AD). For example, stress or glucocorticoid administration can increase amyloid ß precursor protein and tau phosphorylation which are involved in synaptic dysfunction and neuronal death associated with AD. Although since AD was first described in 1906 at a conference in Tubingen, Germany by Alois Alzheimer our knowledge of neuropathological and neurochemical alterations of AD has been impressively increased, at present, pharmacotherapy is symptomatic at best and has no influence on the progression of the disorder. It is generally believed that most of the drugs developed as disease modifiers have failed in clinical trials because treatment started too late, i.e., after the clinical onset of AD. Because AD pathology begins several years prior to the clinical diagnosis, it is imperative to identify subjects at high risk to develop the disorder. Consequently, the search for putative risk factors has gained importance. ApoE4, diabetes/metabolic syndrome, cardiovascular disorders, and a low cognitive reserve are established risk factors for AD. The focus of this review is on stress and glucocorticoids as potential factors increasing the risk to develop AD.

KW - Alzheimer's disease

KW - Animal model

KW - Glucocorticoids

KW - Risk factor

KW - Stress

UR - http://www.scopus.com/inward/record.url?scp=85046104438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046104438&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2018.04.017

DO - 10.1016/j.phrs.2018.04.017

M3 - Review article

AN - SCOPUS:85046104438

VL - 132

SP - 130

EP - 134

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

ER -